Products

Daclizumab (TP-095CL)

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.      

Specifications
Classify
Protein therapeutics that interfere with a molecule or organism: Transplantation
Therapeutic
Daclizumab
Trade Name
daclizumab
Function
Humanized igG1 mAb that blocks cellular immune response in graft rejection by binding the alpha chain of cD25 (iL2 receptor) and thereby inhibiting the iL2-mediated activation of lymphocytes
Examples of Clinical Use
Prophylaxis against acute allograft rejection in patients receiving renal transplants
References
Synonyms
Anti-IL-2, Humanized antiCD25, Ig gamma-1 chain C region
UniProt
P01857
Genbank
J00228

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-871-5806    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2017 Creative-Biolabs All Rights Reserved